CBD, Companies, Europe, HT Premium, Medical, News, North America, USA

After approval of first cannabis-based drug in USA, what’s next?

Analysis from HempToday, the voice of the global hemp industries.
Share this:
  • 16
  • 3

Recent approval of GW Pharmaceutical’s cannabidiol-based drug Epidiolex in the United States not only will soon give patients needed relief, but can spur further research into cannabinoids as well as expansion of the CBD sector overall. That could set off a cycle that would result in a greater number of treatment options for patients, GW has said.

GW made cannabis history June 25, 2018 when it earned approval from the U.S. Food & Drug Administration (FDA) for Epidiolex, a drug crafted as a treatment for two forms of childhood epilepsy. It is the first cannabis-derived prescription drug to gain federal approval in the United States.

You need to login to view the rest of the content. Please . Not a Member? Join Us

Get Hemp Industry Updates

* indicates required

Do you want event updates?